Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01679470 · ClinicalTrials.gov registry record · NA
Efficacy Study of AuroLase Therapy in Subjects With Primary and/or Metastatic Lung Tumors
A NA study, sponsored by Nanospectra Biosciences.
- Terminated
- Registry status
- NA
- Development phase
- 1
- Enrollment target
NCT01679470: Clinical Trial NA study, sponsored by Nanospectra Biosciences.
NCT01679470 is a NA study that was terminated before completion, run by Nanospectra Biosciences. The registered enrollment target is 1 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01679470, a NA study, was terminated before completion, sponsored by Nanospectra Biosciences.
- TERMINATED
- Registry status
- NA
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is an open-label, single-center, single-dose efficacy pilot study of AuroLase Therapy in the treatment of subjects with primary and/or metastatic tumors of the lung where there is airway obstruction. In this study patients will be given a systemic IV infusion of particles and a subsequent escalating dose of laser radiation delivered by optical fiber via bronchoscopy.
Interventions
- DEVICE AuroLase Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2012-10 |
| Est. Completion | 2014-06 |
| Phase | NA |
Why NCT01679470 stopped before completion
NCT01679470 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which AuroLase Therapy is the first listed.
NCT01679470 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01679470 about?
NCT01679470 is a clinical study titled "Efficacy Study of AuroLase Therapy in Subjects With Primary and/or Metastatic Lung Tumors". This is an open-label, single-center, single-dose efficacy pilot study of AuroLase Therapy in the treatment of subjects with primary and/or metastatic tumors of the lung where there is airway obstruction. In this study patients will be given a systemic IV infusion of particles and a subsequent escal...
What is the current status of trial NCT01679470?
This trial is currently terminated. It is a NA study. The enrollment target is 1 participants. The study started on 2012-10. Estimated completion is 2014-06.
What interventions are being tested in trial NCT01679470?
The interventions under investigation include: AuroLase Therapy (DEVICE).
Who is sponsoring clinical trial NCT01679470?
This trial is sponsored by Nanospectra Biosciences, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01679470's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia